Nordic Nanovector ASA – Results for the Third Quarter 2017

Nordic Nanovector is ready to initiate the pivotal Phase 2b study, PARADIGME, with Betalutin® in patients with relapsed, anti-CD 20 Ab-refractory FL (R/R FL), a high unmet medical need group, pending approval of the proposed trial design from regulatory authorities. Go to full presentation here PARADIGME is designed to generate the clinical data needed to […]

Nordicna Novector

41 MNOK til tre prosjekter innen legemiddelproduksjon

I følge Dagens Medisin får tre prosjekter innen legemiddelproduksjon og produksjon av medisinsk utstyr 41 millioner kroner av Forskningsrådet. To av prosjektene involverer porteføljebedriftene Oncoinvent og Nordic Nnaovector.   Dette er prosjekter som ifølge Forskningsrådet bygger videre på godt etablerte fagmiljøer og aktører, og som skal bidra til å trekke norsk helsenæring i ønsket retning, […]

Photocure with excellent Q3 results

Our portfolio company Photocure ASA is on the roll in the U.S and reported a revenue growth of 45% for this important market in the third quarter of 2017. Following the new Medicare reimbursement from 2018, Photocure increases the annual revenue ambition for 2020 to a range of USD 20 to 25 million.   “Our third […]

Improved reimbursement for Photocure in the U.S.

Our portfolio company Photocure with more positive news from the the U.S. market. The United States Centers for Medicare & Medicaid Services (CMS) will from January 1, 2018  reimburse hospital outpatient departments for certain Blue Light Cystoscopy (BLC™) with Cysview®.   “The effectiveness and benefits of using Blue Light Cystoscopy (BLC) with Cysview for improved detection […]

Targovax with encouraging third quarter

Our portfolio company Targovax presented third quarter results on November 2nd. Highlights included several patent grants, new collaborations and updated survival rates.    Watch webcast of the third quarter presentation here   Download third quarter presentation here Highlights: Research & Development Targovax presented data from three trials at the annual meeting of the European Society of Molecular Oncology (ESMO) […]

Updated results to be presented at ASH in December

Our portfolio company Nordic Nanovector will present updated results from the phase I/II trial of Betalutin in non-Hodgkin lymphoma in a poster at the American Society of Hematology (ASH) meeting, 9-12 December 2017 in Atlanta, US.   The dataset includes 55 evaluable patients. Data from patients receiving the two most promising dosing regimens in the […]

Zelluna Immunotherapy appoints Miguel Forte as CEO

Our portfolio company Zelluna Immunotherapy has appointed Miguel Forte as chief executive officer (CEO) to drive Zelluna through next stage of international clinical-phase development.   Zelluna Immunotherapy is a biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need. “Zelluna has a very strong foundation, […]

Ultimovacs henter inn 125 millioner

Vårt porteføljeselskap Ultimovacs sikrer finansiering til videre utvikling av kreftvaksine ved å hente inn 125 millioner kroner. Selskapet er nå priset til 675 millioner.   Kreftvaksineselskapet Ultimovacs AS henter NOK 125 millioner til videre dokumentasjon av vaksinen til behandling av kreft og en utredning av om vaksinen også kan utvikles til å brukes som en forebyggende […]

Targovax reports 100 % one year survival rate from trial

Our portfolio company Targovax announces encouraging one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer. The trial is an open label, phase I/II trial of the cancer vaccine TG01/GM-CSF in combination with gemcitabine as adjuvant therapy for treating patients with resected adenocarcinoma of the pancreas. The […]